Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Cited by (999)

Items 801–900 of 999

1. A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin
   Nozomu Yamasaki, Yoshifumi Tamura, Hideyoshi Kaga, Motonori Sato, Mai Kiya, Satoshi Kadowaki, Ruriko Suzuki, Yasuhiko Furukawa, Daisuke Sugimoto, Takashi Funayama et al. · 2020 · Diabetes Obesity and Metabolism
2. Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?
   Rune E. Kuhre, Carolyn Fiona Deacon, Nicolai J. Wewer Albrechtsen, Jens Juul Holst · 2021 · Diabetes Obesity and Metabolism
3. Quiz
   Jatinder Kohli, Stanley Goldfarb · 2017 · American Journal of Kidney Diseases
4. Sotagliflozin Modulation of SIRT1/Nrf2 and PI3K/AKT Signaling Pathway Ameliorates Experimental Liver Fibrosis in Rats
   Hossein Mostafa Elbadawy, Mohannad A. Almikhlafi, Mohammed H. Alsubhi, Aya A. Shokry, Hany M. Fayed, Bassim M. S. A. Mohamed, Sherif Mahmoud Afifi, Tuba Esatbeyoglu, Reda M. S. Korany, Marawan A. Elbaset · 2025 · Oxidative Medicine and Cellular Longevity
5. The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease; a narrative review
   Mihaela Simona Popoviciu, Lorena Păduraru, Mominur Rahman, Fatema Akter Supti, Roxana Adriana Stoica, Delia Reurean‐Pintilei, Cristina Ioana Bica, Simona Daniela Cavalu · 2024 · Journal of Mind and Medical Sciences
6. Recent advances in understanding the mechanisms in skeletal muscle of interaction between exercise and frontline antihyperglycemic drugs
   Sean Alec Newsom, Matthew M. Robinson · 2024 · Physiological Reports
7. Prise de position de la Société Francophone du Diabète (SFD) : évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2
   Bernard Bauduceau, L. Bordier, J. Bringer, G. Chabrier, Bernard H. Charbonnel, Emmanuel Cosson, Patrice Darmon, B. Detournay, Pierre Fontaine, Pierre Gourdy et al. · 2019 · Médecine des Maladies Métaboliques
8. Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes
   Shivani Sharma, Amit Mittal, Shubham Kumar, Anu Mittal · 2021 · Current Diabetes Reviews
9. One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
   Stefano Radellini, Enrica Vigneri, Valentina Guarnotta, Felicia Pantò, Carla Santos de Souza Giordano · 2021 · Diabetes Therapy
10. SGLT2 inhibitor versus carbohydrate-restricted isocaloric diet: reprogramming substrate oxidation in type 2 diabetes
    Hiroyuki Igarashi, Hiroshi Uchino, Momoko Kanaguchi, Kaori Hisanaga, Genki Sato, Fukumi Yoshikawa, Masashi Furuta, Naohiro Washizawa, Shuki Usui, Masahiko Miyagi et al. · 2023 · Diabetology & Metabolic Syndrome
11. The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator
    Roopameera Thirumathyam, Erik Arne Richter, Gerrit van Hall, Jens Juul Holst, Mogens Fenger, Jens Peter Goetze, Ulrik Dixen, Niels Grove Vejlstrup, Sten Madsbad, Per Lav Madsen et al. · 2024 · Cardiovascular Diabetology
12. Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects
    Xi Chen, Devjit Tripathy, ROBERT J. CHILTON, ANDREA A. HANSIS-DIARTE, Marzieh Salehi, Carolina Solis‐Herrera, Eugênio Cersósimo, Ralph Anthony DeFronzo · 2024 · Diabetes
13. The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study
    Hirokazu Kakuda, Junji Kobayashi, Masaru Sakurai, Masahiro Kakuda, Noboru Takekoshi · 2017 · Journal of Clinical Medicine Research
14. EMPA-REG OUTCOME: The Endocrinologist's Point of View
    Leigh Perreault · 2017 · The American Journal of Cardiology
15. Deterioration of insulin release rate response to glucose during oral glucose tolerance test is associated with an increased risk of incident diabetes in normal glucose tolerance subjects
    Yuanyuan Li, Shi-Hui He, Yao Sun, Guangwei Li, Qingsong Xu, Chen Wang, Weiping Jia · 2017 · IUBMB Life
16. Sodium–Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus
    Rinkoo Dalan · 2018 · Cardiology in Review
17. Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo
    Kyu Hang Lee, Sang Don Lee, Namdu Kim, Kwee Hyun Suh, Young‐Hoon Kim, Sang Soo Sim · 2019 · Korean Journal of Physiology and Pharmacology
18. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study
    Yoshiro Fushimi, Atsushi Obata, Junpei Sanada, Yuichiro Iwamoto, Akiko Mashiko, Megumi Horiya, Akiko Mizoguchi-Tomita, Momoyo Nishioka, Yuki Kan, Tomoe Kinoshita et al. · 2020 · Journal of Diabetes Research
19. Glucagon in type 1 diabetes patients receiving SGLT2 inhibitors: A Friend or Foe?
    Tomoyasu Fukui, Makoto Ohara, Sho‐ichi Yamagishi · 2020 · Diabetes/Metabolism Research and Reviews
20. Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study
    Akira Kurozumi, Yosuke Okada, Yoshiya Tanaka · 2020 · Endocrine Journal
21. The Association between Urinary Glucose and Renal Uric Acid Excretion in Non-diabetic Patients with Stage 1-2 Chronic Kidney Disease
    Xinhui Feng, Yuqi Zheng, Haochen Guan, Xun Clare Zhou, Ying Xu, Xiaoli Zhang, Chensheng Fu, Jing Xiao, Zhibin Ye · 2020 · Endocrine Research
22. Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function
    Alena Welters, Eckhard Lammert · 2021 · Handbook of experimental pharmacology
23. Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus
    Benjamin Burggraaf, Nadine M. C. Pouw, Salvador Fernández‐Arroyo, Leonie C van Vark-van der Zee, Gert-Jan M van de Geijn, Erwin Birnie, Jeannine Huisbrink, Ellen M van der Zwan, Wouter W de Herder, Monique T Mulder et al. · 2022 · European Journal of Endocrinology
24. Addition of canagliflozin to insulin improves glycaemic control and reduces insulin dose in patients with type 2 diabetes mellitus: A randomized controlled trial
    Keiichi Torimoto, Yosuke Okada, Yukiko Goshima, Akemi Tokutsu, Yasunori Sato, Yoshiya Tanaka · 2019 · Diabetes Obesity and Metabolism
25. Renal effects of sodium–glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment
    Matthew R. Weir · 2019 · Postgraduate Medicine
26. Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study
    Takeshi Osonoi, Atsuko Tamasawa, Yusuke Osonoi, Kensuke Ofuchi, Makoto Katoh, Miyoko Saito · 2019 · Diabetes Therapy
27. An atypical hyperosmolar hyperglycemic state and diabetic ketoacidosis induced by sodium–glucose cotransporter-2 inhibitors: A case report
    Chen‐Ti Wang, Che-Wei Chang, Yung‐Chuan Lu, Hing‐Chung Lam, Shu-Ju Ku, Kuo-Bin Tseng, Yu-Hsi Kao · 2019 · Journal of the Formosan Medical Association
28. Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study
    Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuno Omori, Kazuhisa Tsuchida, Aika Miya et al. · 2021 · Journal of Diabetes Investigation
29. Case of sodium–glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis
    Huei Li Yeoh, Marilyn Lee, Woei Jack Pan, Hean Yee Ong · 2021 · BMJ Case Reports
30. The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition
    Maria Moreno-Lopez, Isaline Louvet, Nathalie Delalleau, Ana Acosta-Montalvo, Julien Thévenet, Gianni Pasquetti, Valéry Gmyr, Julie A. Kerr-Conte, François N. Pattou, Caroline Bonner et al. · 2024 · Diabetes Obesity and Metabolism
31. Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy
    Zhicheng Gao, Jiaqi Bao, Yilan Hu, Junjie Tu, Lifang Ye, Lihong Wang · 2023 · Current Drug Targets
32. Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study
    Deniz Çetın, E.P. Bilgili, Ömer Komaç, Merve Yetişken, Engın Güney · 2025 · Medicina
33. Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
    HARPREET SINGH BAJAJ, Bernard Zinman · 2018 · Physiology
34. Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
    Muhammad A Abdul‐Ghani, Ralph Anthony DeFronzo · 2021 · Expert Opinion on Pharmacotherapy
35. SGLT2i Increase Endogenous Glucose Production: That’s Good News!
    Andrea Giaccari · 2022 · Diabetes Care
36. Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review
    Sopak Supakul, Yurika Nishikawa, Masanori Teramura, Tetsuro Takase · 2022 · Medicina
37. Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass
    Antonio Ferreira, Ahmed F. Emara, David Herzig, Andreas Melmer, Andreas P. Vogt, Christos Theodoros Nakas, Andrea Facchinetti, Chiara Dalla Man, Lia Bally · 2022 · BMJ Open
38. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials
    Awadhesh Kumar Singh, Ritu Singh, Ritu Singh · 2023 · Endocrine Practice
39. Isotopomer analyses with the tricarboxylic acid cycle intermediates and exchanging metabolites from the rat kidney
    Eunsook S. Jin, Xiaodong Wen, Craig R. Malloy · 2023 · NMR in Biomedicine
40. Comparison Between SGLT2 Inhibitors and Lactation: Implications for Cardiometabolic Health in Parous Women
    María A. Ramos-Román · 2024 · Metabolic Syndrome and Related Disorders
41. Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: study protocol for the Dapagliflozin, Exercise Training and physicAl function (DETA) randomised controlled trial
    Jack Alistair Sargeant, Ehtasham Ahmad, Emily James, Luke A. Baker, Joanna M Bilak, Nicole A. Coull, Gaurav Singh Gulsin, James A. King, Kamlesh Khunti, Emma Redman et al. · 2024 · BMJ Open
42. Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats
    Aline Bomfim Vieira, Sarah M. Cavanaugh, Bianca Torres Ciambarella, Marcus Vinícius Ribeiro Machado · 2025 · Frontiers in Veterinary Science
43. SGLT-2i—A Useful Tool for Real-Life Metabolic and Body Weight Control in Type 2 Diabetes Mellitus Patients
    Mihaela Simona Popoviciu, Teodor Salmen, Delia Reurean‐Pintilei, Vlad Mihai Voiculescu, Anca Pantea Stoian · 2025 · Medicina
44. Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy
    Jennifer Nicole Clements, Heather P. Whitley, Jennifer J. D’Souza, Ben Gross, Rick Hess, Sara Wilson Reece, Chad K. Gentry, Kayce M. Shealy · 2015 · Current Medical Research and Opinion
45. Isotopic Tracers for the Measurement of Metabolic Flux Rates
    Carine Beysen, Marc K. Hellerstein, Scott Turner · 2014 · Springer eBooks
46. Sodium–Glucose Cotransporters
    Gregory R. Bebernitz · 2016 · Elsevier eBooks
47. Posicionamiento en guías nacionales e internacionales de los inhibidores del cotransportador sodio-glucosa tipo 2
    Carlos Morillas · 2016 · Medicina Clínica
48. SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
    Dimitrios Patoulias · 2017 · Acta Medica (Hradec Kralove Czech Republic)
49. Euglycemic diabetic ketoacidosis in type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitors. A report on two cases
    Antonio Burgio, Maurizio Alletto, Salvatore Amico, Umberto Castiglione, Giovanni Fulco, Concetta Groppuso, Gianfranco Gruttadauria, Susanna Salvaggio, A Grande, Federico Vancheri · 2018 · Italian Journal of Medicine
50. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes
    Mohamed Asrih, Karim Gariani · 2019 · Current Diabetes Reviews
51. Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial
    Fumio Sawano, Nozomu Kamei, Mitsue Miyahara, Kyoko Kobuke, Shuhei Nakanishi, Chihiro Nagano, Hideki Nojima, Shusaku Maeda, Hiroshi Watanabe, Rui Kishimoto et al. · 2021 · Diabetology International
52. Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
    Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile · 2021 · Advances in Therapy
53. Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease
    Fabie Oguz, Nathalie Demoulin, Jean Paul Thissen, Michel Y. Jadoul, Johann Morelle · 2021 · Acta Clinica Belgica
54. Methods for Quantifying Insulin Sensitivity and Determining Insulin Time-Action Profiles
    Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch · 2014 · Springer eBooks
55. Naturally Occurring SGLT2 Inhibitors: A Review
    Habib Yaribeygi, Milad Ashrafizadeh, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar · 2021 · Advances in experimental medicine and biology
56. Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes
    Satoru Bando, Raishi Ichikawa, Tomomi Taguchi, Kazumi Fujimoto, Tetsuya Motomiya, Madoka Taguchi, Koji Takano, Masayoshi Shichiri, Takeshi Miyatsuka · 2022 · Endocrine Journal
57. Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
    Atsushi Tanaka, Takumi Imai, Michio Shimabukuro, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Hirotaka Watada, Junya Ako, Koichi Node, the CANDLE trial investigators · 2022 · Cardiovascular Diabetology
58. Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials
    Alaa Mohamed Zaki, Dina Essam Abo‐elnour, Yomna Emad Abdalla, Rehab Yosri Hassan, Moaz Khaled Salama, Toka Elboraay, Ibrahim Abdelmonaem Abdelhaleem · 2022 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
59. Ketone production and excretion even during mild hyperglycemia and the impact of sodium-glucose co-transporter inhibition in type 1 diabetes
    Daniel Scarr, Leif Erik Lovblom, Hongping Ye, Hongyan Liu, ABDULMOHSEN M.K. BAKHSH, Natasha J. Verhoeff, Thomas M. S. Wolever, Patrick R. Lawler, Kumar Sharma, David Z.I. Cherney et al. · 2023 · Diabetes Research and Clinical Practice
60. Systems Pharmacology Modeling in Type 2 Diabetes Mellitus
    Jim Bosley, Tristan S. Maurer, Cynthia J. Musante · 2016 · AAPS advances in the pharmaceutical sciences series
61. Effects of different dosages of Sodium-Glucose Transporter 2 Inhibitors on lipid levels in patients with type 2 diabetes mellitus
    TingYu Cai, Yang Gao, Li Zhang, Ting Yang, Chen Qiu · 2020 · Medicine
62. How attractive is the combination of a sodium glucose co‐transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes?
    Guntram Schernthaner, Marie Helene Schernthaner-Reiter · 2015 · Diabetes Obesity and Metabolism
63. Choosing the Best Oral Diabetic Agents in T2 Diabetes Mellitus-Physicians Challenge
    Bijaya Mohanty · 2018 · Journal of Diabetes & Metabolism
64. Mechanistic insights from sequential combination therapy with a sodium glucose co‐transporter‐2 inhibitor and a dipeptidyl peptidase‐4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin
    Sumie Okahata, Kentaro Sakamoto, Takako Mitsumatsu, Yuko Kondo, Shoji Tanaka, Teruo Shiba · 2018 · Diabetes Obesity and Metabolism
65. Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus
    Yasuhiro Watanabe, Nobuichi Kuribayashi, Daigaku Uchida, Daisuke Suzuki, Mitsutoshi Kato, Daiji Nagayama, Hiroshi Ohashi, Masahiro Ohira, Atsuhito Saiki, Ichiro Tatsuno · 2018 · Diabetes Therapy
66. Normal Glucose Physiology
    Mazen Alsahli, John E. Gerich · 2014 · Elsevier eBooks
67. Correction to: Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus
    Yasuhiro Watanabe, Nobuichi Kuribayashi, Daigaku Uchida, Daisuke Suzuki, Mitsutoshi Kato, Daiji Nagayama, Hiroshi Ohashi, Masahiro Ohira, Atsuhito Saiki, Ichiro Tatsuno · 2020 · Diabetes Therapy
68. Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan
    Ryo Suzuki, Shingo Shoji, Yoko Yoshinaga, Yoshinori Kosakai, Mami Shintani‐Tachi · 2025 · Diabetes Obesity and Metabolism
69. Contribution of metabolism-independent glucose sensing to metabolic homeostasis
    Nadia Rashid, Kavaljit H. Chhabra · 2025 · Trends in Endocrinology and Metabolism
70. Renal Protection at a Metabolic Cost: A Systematic Review and Meta‐Analysis of Perioperative Use of Sodium–Glucose Cotransporter 2 Inhibitors
    Elsayed Balbaa, Ahmed Farid Gadelmawla, Ahmed Ibrahim, AlMothana Manasrah, Ahmed Elbataa, Abdalhakim R. M. Shubietah, Mohamed S. Elgendy, Ahmed Sobhy, Ahmed Mansour, Ameer Awashra et al. · 2026 · Endocrinology Diabetes & Metabolism
71. An integrative view on glucagon function and putative role in the progression of pancreatic neuroendocrine tumours (pNETs) and hepatocellular carcinomas (HCC)
    Bárbara Ferreira, Adrián Heredia, Jacinta Serpa · 2023 · Molecular and Cellular Endocrinology
72. Advances in clinical research on glucagon
    Ichiro Horie, Norio Abiru · 2024 · Diabetology International
73. Mendelian randomization study of sodium–glucose cotransporter 2 inhibitors in cardiac and renal diseases
    Lei Chen, Yongdi Zuo, Manrong He, Lijin Duo, Wanxin Tang · 2024 · Journal of International Medical Research
74. Computational structural studies of SGLT2-related polypharmacy
    Aled Rhys Lloyd, Karl Austin‐Muttitt, Jonathan G.L. Mullins · 2025 · PLoS ONE
75. SGLT inhibition in patients with type 1 diabetes
    Clayton A. Dehn · 2014 · The Lancet Diabetes & Endocrinology
76. Adjunct Therapies In Type 1 Diabetes
    Paresh Dandona, Nitesh D Kuhadiya, Husam Ghanim, Ajay Chaudhuri · 2016 · Endocrine Practice
77. Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
    Richard E. Pratley, Eugênio Cersósimo · 2017 · Clinical Diabetes
78. Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal
    Nishant Garodia, Vishal Gupta, William J. Canovatchel, BN Lokesh, Ravi Santani · 2017 · Indian Journal of Endocrinology and Metabolism
79. A single center retrospective analysis of SGLT2i-associated diabetic ketoacidosis in Bangkok: The role of point-of-care blood ketone testing
    Yotsapon Thewjitcharoen, Ekgaluck Wanothayaroj, Chattip Tammawiwat, Areeya Malidaeng, Nalin Yenseung, Soontaree Nakasatien, Sirinate Krittiyawong, Thep Himathongkam · 2018 · Journal of Clinical and Translational Endocrinology Case Reports
80. Cardiovascular effects of sodium glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus
    Surender Kumar, Pradeep Talwalkar, Sambit Das, Soumik Goswami · 2019 · Indian Journal of Endocrinology and Metabolism
81. Potential mechanisms underlying cardiovascular protection by sodium glucose cotransporter 2 inhibitors (empagliflozin)
    Ibragim S. Sabirov, Ilkhom T. Murkamilov, Victor V. Fomin · 2021 · Complex Issues of Cardiovascular Diseases
82. A REVIEW ON PHARMACOLOGY AND THERAPEUTIC EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    AJAY CHADEVE · 2020 · Asian Journal of Pharmaceutical and Clinical Research
83. Identification of a Novel Mutation in Patients with Type A Insulin Resistance Syndrome
    Liling Zhao, Hongmei Dai, Qin Zhang, Wenmu Hu, Ping Jin · 2022 · Human Heredity
84. GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns
    George Dimitriadis, Vaia Lambadiari · 2022 · The Journal of Clinical Endocrinology & Metabolism
85. Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: case report and literature review
    Malak S. El Ess, Mohamed Elrishi · 2023 · Annals of Medicine and Surgery
86. Nanoparticles with SGLT2 inhibitory activity: Possible benefits and future
    Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, Nikolay K. Shakhpazyan, Prashant Kesharwani, Amirhossein Sahebkar · 2023 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
87. Empagliflozin, a sodium‐glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome
    Yunhao Li, Zhanming Zhang, Zheming Zhang, Ningning Zheng, Xudong Ding · 2024 · Journal of Cellular Physiology
88. A Case Study of Emphysematous Cystitis in a Non-diabetic Patient Following Empagliflozin Use: An Uncommon Presentation
    Nicolette Busuttil, Rami Khalaf, Ian Galea, Jonathan Calleja · 2024 · Cureus
89. Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data
    Alex E. Henney, David R. J. Riley, Megan Heague, Theresa Hydes, Matthew Anson, Uazman Alam, Daniel James Cuthbertson · 2024 · Diabetes Obesity and Metabolism
90. Quantification of Insulin Action in Human Subjects
    Andrew J. Krentz, Christian Weyer, Marcus Hompesch · 2019 · Springer eBooks
91. Mise au point sur le profil de tolérance de la classe des inhibiteurs de SGLT2
    Pierre Gourdy · 2019 · Médecine des Maladies Métaboliques
92. Sodium-Glucose Cotransporter 2 Inhibitors: Mechanisms of Action and Various Effects
    Kyung‐Soo Kim · 2019 · Journal of Korean Diabetes
93. Canagliflozin for Type 2 diabetes: an up-to-date evidence summary
    Aris Liakos, Thomas Karagiannis, Eleni Bekiari, Απόστολος Τσάπας · 2015 · Diabetes Management
94. Type 2 Diabetes Mellitus. From the start – combination therapy
    Francesco Indovina, Pierpaolo Falcetta, Stefano Del Prato · 2018 · Diabetes Mellitus
95. Sodium–Glucose Cotransporter 2 Inhibitors and the Kidney
    Ralph Anthony DeFronzo, Muhammad A Abdul‐Ghani · 2021 · Diabetes Spectrum
96. Sodium Glucose Cotransporter 2 Inhibitors Across the Spectrum of Cardiovascular Kidney Metabolic Syndrome
    Kevin Bryan Lo, Karim Iskarous, Rajiv Sankaranarayanan · 2025 · Cardiology Clinics
97. Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial
    Bryony Beal, Luke Buizen, Emily K. Yeung, Lauren Heath, Lauren Houston, David Z.I. Cherney, Meg Jardine, Carol A. Pollock, Clare Gabrielle Arnott, Sradha S. Kotwal et al. · 2025 · Nephrology Dialysis Transplantation
98. Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator
    Roopameera Thirumathyam, Erik Arne Richter, Gerrit van Hall, Nicoline R. Andersen, Per Lav Madsen, Jens Juul Holst, Sten Madsbad, Nils B. Jørgensen · 2025 · Diabetologia
99. Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysis
    Davood Semirani-Nezhad, Khatere Roozbehi, Arman Soltani Moghadam, Elham Ebrahimi, Keyvan Salehi, Anahita Hashempoor, Sima Shamshiri, Tara Azardar, Mahshad Sabri, Ali Moradi et al. · 2026 · International Journal of Cardiology Cardiovascular Risk and Prevention
100. Dapagliflozin regulates autophagy in nephropathy associated with non-diabetic obesity via elevated plasma β-hydroxybutyrate levels
     Yan Kong, Xiaoyue Peng, Wenying Fan, Li Zhang, Yijie Wu, Miaoyan Zheng, Chunyan Shan · 2026 · Biochemical Journal